There is compelling evidence that bacteria, parasites, viruses, and fungi are developing resistance to antimicrobials. As a result, infections in humans, animals, and plants are becoming increasingly difficult, and in some cases impossible, to treat.
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published – Biotech Investments
EQS-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement/9 Month figures APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month